SCHEMBL5793082

SCHEMBL5793082

CSc1nccc(-c2c(-c3cccc(C)n3)nc3ccc(Cl)cn23)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 2/20 0.51
PIK3CD O00329 1/20 0.51
PIK3R1 P27986 1/20 0.51
CSNK1E P49674 2/20 0.45
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
GLA P06280 1/20 0.43
GAA P10253 3/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPK14 Q16539 2/20 0.41
MAPK13 O15264 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
TGFBR1 P36897 3/20 0.39
CDK2 P24941 2/20 0.38
CCNA2 P20248 1/20 0.38
CDK5 Q00535 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL413422 0.87 CSNK1E (0.47) MAP3K14CSNK1EMAPK14MAPK13MAPK12
SCHEMBL414562 0.87 MAPK14 (0.41) MAP3K14PIK3CDPIK3R1CSNK1EKDM4E
SCHEMBL415015 0.86 MAP3K14 (0.71) MAP3K14PIK3CDPIK3R1CSNK1EGAA
SCHEMBL413379 0.84 TGFBR1 (0.42) MAP3K14CSNK1EKDM4EALDH1A1L3MBTL1
SCHEMBL413663 0.83 ALDH1A1 (0.52) CSNK1EKDM4EALDH1A1L3MBTL1GLA
SCHEMBL412478 0.82 MAP3K14 (0.48) MAP3K14PIK3CDPIK3R1GAAMAPT
SCHEMBL412987 0.81 TGFBR1 (0.45) TGFBR1HTR6
SCHEMBL5791823 0.79 MAPK14 (0.46) CSNK1EKDM4EALDH1A1L3MBTL1GLA
SCHEMBL5788274 0.77 PIK3CD (0.45) MAP3K14PIK3CDPIK3R1KDM4EALDH1A1
SCHEMBL5791851 0.76 CSNK1E (0.52) CSNK1EKDM4EALDH1A1L3MBTL1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135517-A1 Imidazolopyridines and methods of making and using the same BIOGEN IDEC MA INC. 2006-06-22 US disclosed
EP-1546112-A4 IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC INC (US) 2006-06-07 EP disclosed
EP-1546112-A2 IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME Biogen Idec MA Inc. (US) 2005-06-29 EP disclosed
WO-2004021989-A2 IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC MA INC. (US) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135517-A1 Imidazolopyridines and methods of making and using the same ALK, ACVR1, ACVRL1 MAP3K14 555/4885PIK3CD 825/4885PIK3R1 2227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.